BioCentury | Jun 23, 2014
Company News

Merck KGaA, Ono Pharmaceutical deal

...Merck is returning rights to Ono for ceralifimod ( ONO-4641 ), a sphingosine 1-phosphate (S1P) receptor...
...has exclusive rights outside of Japan, Korea and Taiwan to the under a 2011 deal. Ceralifimod...
...circumstances” for MS treatments and the “large and extensive Phase III studies required.” Merck said ceralifimod...
BioCentury | Jun 18, 2014
Company News

Merck returning S1P receptor agonist to Ono

...Merck KGaA (Xetra:MRK) is returning rights to Ono Pharmaceutical Co. Ltd. (Tokyo:4528) for ceralifimod ( ONO-4641...
...has exclusive rights outside of Japan, Korea and Taiwan to the under a 2011 deal. Ceralifimod...
...circumstances" for MS treatments and the "large and extensive Phase III studies required." Merck said ceralifimod...
BioCentury | May 28, 2012
Product Development

Devil is in the dosing

...S1PR1, while dialing out interaction with S1PR3. However, Phase II data reported in April for ONO-4641...
...from Ono Pharmaceutical Co. Ltd. and Merck KGaA , show cardiovascular signals similar to Gilenya's. ONO-4641...
...at baseline in the Gilenya Phase II trial (2.8-3.4) vs. the ONO-4641 trial (0.9-1.4). However, ONO-4641...
BioCentury | Apr 23, 2012
Clinical News

ONO-4641: Phase II data

...407 patients aged 18-55 with RRMS showed that once-daily 0.05, 0.1 and 0.15 mg oral ONO-4641...
...in 4-week intervals for 26 weeks vs. placebo. Specifically, patients receiving low-, mid- and high-dose ONO-4641...
...all). Grade 4 lymphopenia occurred in 1% and 4% of patients receiving mid- and high-dose ONO-4641...
BioCentury | Apr 18, 2012
Clinical News

Ono's S1P receptor agonist meets RRMS endpoint

...Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528) said once-daily 0.05, 0.1 and 0.15 mg doses of oral ONO-4641...
...DreaMS trial to treat relapsing-remitting multiple sclerosis (RRMS). Specifically, patients receiving low-, mid- and high-dose ONO-4641...
...presented at the American Academy of Neurology meeting in New Orleans, which begins April 21. ONO-4641...
BioCentury | Mar 19, 2012
Strategy

Remaking Merck Serono

...its own play in S1P, licensing exclusive rights outside of Japan, Korea and Taiwan to ONO-4641...
...Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528) Exclusive rights outside of Japan, Korea and Taiwan to ONO-4641...
BioCentury | Oct 10, 2011
Company News

Merck KGaA, Ono Pharmaceutical deal

...rights outside of Japan, Korea and Taiwan to develop and commercialize multiple sclerosis (MS) compound ONO-4641...
BioCentury | Oct 5, 2011
Company News

Merck Serono in-licenses Ono's S1P receptor agonist

...rights outside of Japan, Korea and Taiwan to develop and commercialize multiple sclerosis (MS) compound ONO-4641...
Items per page:
1 - 8 of 8